Global Immunohistochemistry Market Size, Share, Trends & Growth Analysis Report – Segmented By Product (Antibodies, Reagents, Equipment, Kits), Application, End-User & Region - Industry Analysis From 2025 to 2033

ID: 2736
Pages: 175

Global Immunohistochemistry Market Report Summary

The global immunohistochemistry (IHC) market was valued at USD 2.16 billion in 2024, is estimated to reach USD 2.32 billion in 2025, and is projected to reach USD 4.11 billion by 2033, growing at a CAGR of 7.4% during the forecast period from 2025 to 2033. The growth of the global immunohistochemistry market is driven by the rising prevalence of cancer and chronic diseases, increasing geriatric population, and expanding use of IHC in disease diagnosis, drug discovery, and biomarker identification. Immunohistochemistry plays a critical role in oncology diagnostics by detecting antigen expression in tissue samples, enabling accurate tumor classification and therapy selection. Advancements in automated staining systems, digital pathology integration, and companion diagnostics are further strengthening market expansion across clinical and research settings.

Key Market Trends

  • Rising global cancer incidence driving demand for tumor biomarker identification
  • Increasing adoption of automated and multiplex IHC platforms
  • Expanding use of IHC in companion diagnostics for targeted therapies
  • Growing applications in drug discovery, neurodegenerative disease research, and forensic science
  • Strategic collaborations between diagnostic companies and pharmaceutical manufacturers

Segmental Insights

  • Based on product, the antibodies segment is expected to lead the global immunohistochemistry market during the forecast period. This dominance is attributed to the mandatory use of primary and secondary antibodies in IHC procedures for cancer, infectious disease, and neurological disorder diagnosis, along with increasing demand for research-grade antibodies in drug development.
  • Based on application, the diagnostics segment accounted for the largest share of the immunohistochemistry market. The high burden of cancer, growing use of IHC in routine pathology workflows, and favorable reimbursement for diagnostic testing are driving sustained demand from hospitals and diagnostic laboratories.
  • Based on end user, the hospitals and diagnostic laboratories segment held the leading share of the global IHC market due to high test volumes, adoption of automated staining instruments, and integration of IHC into standard cancer diagnostic protocols.

Regional Insights

The global immunohistochemistry market demonstrates strong regional variation driven by healthcare infrastructure, disease prevalence, and research activity.

  • North America led the global immunohistochemistry market in 2024 due to high cancer incidence, strong reimbursement frameworks, advanced diagnostic infrastructure, and widespread adoption of automated IHC systems in clinical laboratories.
  • The Asia-Pacific region is expected to register the fastest CAGR during the forecast period, supported by rapid economic development, expanding healthcare infrastructure, rising cancer prevalence, and increasing investments in diagnostic laboratories across China, India, South Korea, and Southeast Asia.
  • Europe is projected to grow at a healthy CAGR owing to increasing cancer screening programs, strong academic research activity, and rising adoption of precision medicine approaches.
  • Latin America and the Middle East & Africa are witnessing gradual market growth driven by improving healthcare access, rising awareness of cancer diagnostics, and expanding laboratory capabilities.

Competitive Landscape

The global immunohistochemistry market is moderately consolidated, with competition centered on antibody portfolios, automation capabilities, assay standardization, and companion diagnostic development. Leading players focus on expanding product pipelines, forming strategic partnerships with pharmaceutical companies, and integrating digital pathology and AI-based analysis tools. Regulatory approvals, assay reproducibility, and clinical validation remain key differentiators. Increasing emphasis on multiplex IHC and personalized medicine is reshaping competitive strategies across global and regional players. Major companies operating in the global immunohistochemistry market include F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.

Global Immunohistochemistry Market Size

The global immunohistochemistry market was valued at USD 2.16 billion in 2024. The size of the global IHC market is forecasted to value USD 4.11 billion by 2033 from USD 2.32 billion in 2025, growing at a CAGR of 7.4% from 2025 to 2033.

The global immunohistochemistry market was valued at USD 2.16 billion in 2024

Immunohistochemistry is a staining procedure done on fresh or stored cancer tissue removed during the biopsy. IHC detects if the cancer cells have hormone receptors on their surface. IHC is majorly used for the diagnosis of cancers, especially tumor antibodies.

MARKET DRIVERS

The growing number of people suffering from chronic diseases is primarily propelling the global immunohistochemistry market growth.

The growing cancer prevalence and the increasing geriatric population drive the immunohistochemistry market growth. Other factors, such as increasing healthcare expenditure and improving healthcare infrastructure, thus leading to more hospitals and diagnostic laboratories daily, are anticipated to result in the growth of the IHC market. In addition, the growing adoption of technologically advanced immunohistochemistry solutions and growing drug discovery & development activities are boosting the market’s growth rate.

Rising approvals of products and the introduction of technologically advanced immunohistochemistry solutions for disease diagnosis further favor the global immunohistochemistry market growth. In addition, the involvement of major players in developing IHC solutions by collaborating with pharmaceutical drug manufacturers to develop and provide IHC companion diagnostic solutions for their immunotherapies offers lucrative opportunities for the market participants operating in the IHC market. Furthermore, rising awareness levels regarding chronic diseases among people are anticipated to promote the demand for immunohistochemistry solutions, which is eventually expected to result in the growth of the IHC market.

Furthermore, the new immunohistochemistry applications in new fields are anticipated to favor the IHC market growth. For instance, a research paper by G.F. Ingrassia, Department of Medical, Surgical and Advanced Technologies, University of Catania, Italy, in collaboration with multiple other institutes published in august of 2022, emphasizes the use of IHC in determining the accurate time of death for a body. The time of death is an essential part of the investigation for the FBI and several investigational organizations; thus, this discovery benefits them. Furthermore, the applications of IHC in detecting several neurodegenerative disorders due to multiple causes, such as cannabidiol use and smoking cigarettes, are expected to support the market’s growth rate.

MARKET RESTRAINTS

However, the lack of specificities associated with IHC techniques and its high setup cost are significant restraints limiting the growth of the global immunohistochemistry market. The lack of specificity of IHC techniques for diagnosing some chronic diseases is a significant challenge for the Immunohistochemistry market. In addition, the considerable burden and high setup cost of IHC equipment in hospitals and diagnostic laboratories among emerging economies are the other factors limiting the growth of the target market.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2024 to 2033

Base Year

2023

Forecast Period

2025 to 2033

Various Analyses Covered

Global, Regional & Country Level Analysis; Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape; Analyst Overview of Investment Opportunities

Segments Analysed

By Application, Technology, Patient Care Setting & Region

Regions Analysed

North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa

Market Leaders Profiled

F. Hoffmann-La Roche AG, Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Merck Millipore, Bio-Rad Laboratories, Inc., PerkinElmer, Inc., Abcam plc, Cell Signaling Technology, Inc., and Bio SB Inc.

SEGMENTAL ANALYSIS

By Product Insights

Based on the product, the antibodies segment is predicted to lead the global immunohistochemistry market during the forecast period. The mandatory use of antibodies in carrying out the immunohistochemistry diagnosis of diseases such as cancer, infectious diseases, and other diseases propels segmental growth. In addition, the growing usage of research antibodies for drug discovery is another major factor contributing to the growth of the antibodies segment.

Based on the product, the antibodies segment is predicted to lead the global immunohistochemistry market

The IHC kits segment is also expected to grow significantly during the forecast period due to the convenience of using kits and the ease it provides in research and development activities for academic and biotechnological procedures. In addition, the sorted kits, which can be used without the hassle of measuring accurate antibody stains for tissues, save a lot of time and help avoid human errors in the procedure, driving the demand for the segment. Furthermore, many key players are now providing kits and assays as the R&D in the field of immunohistochemistry rises leading to segment growth.

By Application Insights

Based on the application, the diagnostic segment accounted for the largest share of the Immunohistochemistry market in 2023. The growing incidence & prevalence of cancer majorly drive the segment's growth. Also, the burden of infectious diseases and the favorable reimbursement scenario for IHC tests is other factors growing the segment's share in the market.

However, due to the multiple immunohistochemistry applications in drug testing, the segment is expected to grow notably during the forecast period. Immunohistochemical staining and histomorphometry quantification are widely used in procedures like drug discovery, drug efficacy, drug repositioning, biomarker expressions, etc. Therefore, they are extensively used by pharmaceutical and biotechnology companies resulting in growth for the segment.

By End User Insights

Based on the end-users, the hospitals & diagnostics laboratories segment captured the largest share of the global IHC market in 2023 and is forecasted to showcase the lead in the global market throughout the forecast period owing to the growing adoption of technological advancements such as automated sample preparation and digital pathology, which have added considerable value. Also, the growing demand for disease diagnosis due to the rise in the incidence of chronic diseases is the other factor that has contributed significantly to the segment’s growth in the recent past.

The research and development segment of the market is also expected to have grown during the forecast period due to the efficiency of the IHC staining procedures and its advantages over traditional special enzyme staining techniques. In addition, IHC has become an essential tool for detecting neurodegenerative disorders via abnormal proteins in research applications for human and animal cells, supporting the segment's growth.

REGIONAL ANALYSIS

Geographically, the IHC market in North America led the worldwide market in 2024, owing to biotech and commercialization advancements. The dominance of the North American region can be credited to the growing adoption of these immunohistochemistry instruments in laboratories & diagnostic centers. In addition, favorable reimbursement policies in countries such as the US and Canada boost the penetration of automated devices, promoting the growth of the IHC market in the North American region. Furthermore, an increase in the number of people with cancer from North American countries is anticipated to demand these immunohistochemistry techniques. For instance, according to the American Cancer Society, in 2019, it was reported that 1,762,450 new cancer cases were diagnosed, and more than 606,880 cancer deaths in the United States.

On the other hand, the IHC market in the Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The rapid growth of the immunohistochemistry market in the Asia-Pacific region is attributed to the economic development in countries such as China, India, South Korea, and Singapore. Besides, the rapid growth of the aging population and the high prevalence of chronic diseases are the other factors fuelling the Asia-Pacific Immunohistochemistry Market development. Moreover, WHO estimates that the annual events of CVDs are predicted to rise by 50% in China between 2010 and 2030.

The IHC market in Europe is expected to grow at a healthy CAGR in the coming years following the Asia Pacific. Constant economic growth and rising disposable income in urban areas are mainly propelling the market demand in this region.

The IHC market in Latin America is also growing due to the increasing incidences of cancer, stabilization of the economy over the past years, growing expenditure on healthcare, developing infrastructure, and rising disposable income.

The IHC Market in the Middle East & Africa is estimated to register a growth rate of 7.3% during the forecast period.

KEY MARKET PARTICIPANTS

Some of the companies that are playing a dominating role in the global immunohistochemistry market include

  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Merck Millipore
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer, Inc.
  • Abcam plc
  • Cell Signaling Technology, Inc.
  • Bio SB Inc.

RECENT MARKET HAPPENINGS

  • In January 2023, two giants in the biosciences industry, Agilent Technologies Inc., and Akoya Biosciences Inc. are entering a partnership to develop a multiplex immunohistochemistry diagnostic solution. The new solutions are expected to help analyze tissues and commercialize workflows for assays for clinical research purposes.
  • In November 2022, Biocare Medical, a primary developer and supplier of antibodies and IHC (immunohistochemistry) equipment, acquired Empire Genomics, a molecular probe provider, to advance its cancer research and diagnostic procedures. The company aims toward better diagnostic facilities and patient results with this project.
  • In November 2022, ImmunoGen's Elahere, a treatment procedure for Platinum-Resistant Ovarian Cancer, now has a companion for the diagnostic procedure with the development of Ventana FOLR1 RxDx test by F. Hoffmann-La Roche AG, which has now been approved for use by the FDA. The test is expected to help identify epithelial ovarian cancer and its treatment possibilities via immunohistochemical assay.
  • In September 2022, aiming toward the development of better pathology teams and for the detection of cancer within lymph nodes from cases of colorectal surgeries, an AI-based pathology solution is being developed via a collaboration between Indica Labs and The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (card).

MARKET SEGMENTATION

This research report on the global immunohistochemistry market has been segmented and sub-segmented into the following categories.

By Product

  • Antibodies
  • Reagents
  • Equipment
  • Kits

By Application

  • Diagnostics
  • Drug testing

By End User

  • Hospitals & Diagnostics Laboratories
  • Research Institutes

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Trusted by 500+ companies. We respect your privacy and never share your data.

Please wait. . . . Your request is being processed

Frequently Asked Questions

What is immunohistochemistry (IHC)?

Immunohistochemistry is a laboratory technique used to detect specific antigens in tissue samples using antigen–antibody reactions, commonly applied in disease diagnosis and research.

What factors are driving the growth of the immunohistochemistry market?

Key growth drivers include the rising prevalence of cancer, increasing demand for accurate disease diagnosis, growing adoption of personalized medicine, and advancements in antibody and staining technologies.

Which applications dominate the IHC market?

Oncology is the dominant application, followed by infectious disease diagnostics, autoimmune disorders, and neuroscience research.

What products are commonly used in immunohistochemistry?

Primary antibodies, secondary antibodies, detection systems, reagents, kits, and automated staining instruments are the main product categories.

Which end users account for the largest market share?

Hospitals and diagnostic laboratories hold the largest share, with significant contributions from research institutes, pharmaceutical companies, and biotechnology firms.

How is automation influencing the IHC market?

Automation improves staining consistency, reduces human error, increases throughput, and is increasingly adopted in high-volume diagnostic laboratories.

What challenges are faced by the immunohistochemistry market?

High costs of antibodies and instruments, variability in test results, and the need for skilled professionals are key challenges.

What trends are shaping the IHC market?

Emerging trends include multiplex IHC, integration with digital pathology, use of AI-based image analysis, and growing demand for companion diagnostics.

How does immunohistochemistry support drug development and clinical trials?

IHC is widely used in drug development to identify biomarkers, assess target expression, and support patient stratification in clinical trials.

. What is the future outlook of the immunohistochemistry market?

The market is expected to grow steadily due to increasing cancer diagnostics demand, expansion of precision medicine, and continued advancements in multiplexing and digital pathology technologies.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample